Susquehanna International Group, LLP Bio Line Rx Ltd. Transaction History
Susquehanna International Group, LLP
- $560 Billion
- Q3 2024
A detailed history of Susquehanna International Group, LLP transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 18,032 shares of BLRX stock, worth $62,390. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,032
Previous 118,180
84.74%
Holding current value
$62,390
Previous $67,000
86.57%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding BLRX
# of Institutions
39Shares Held
4.24MCall Options Held
46.5KPut Options Held
6.3K-
Highbridge Capital Management LLC New York, NY1.01MShares$3.49 Million0.05% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL866KShares$3 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.82 Million4.05% of portfolio
-
Morgan Stanley New York, NY198KShares$683,4780.0% of portfolio
-
Values First Advisors, Inc.166KShares$575,9130.02% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $213M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...